Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10,091 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Radiomics to evaluate interlesion heterogeneity and to predict lesion response and patient outcomes using a validated signature of CD8 cells in advanced melanoma patients treated with anti-PD1 immunotherapy.
Sun R, Lerousseau M, Briend-Diop J, Routier E, Roy S, Henry T, Ka K, Jiang R, Temar N, Carré A, Laville A, Hamaoui A, Laurent PA, Rouyar A, Robert C, Robert C, Deutsch E. Sun R, et al. Among authors: roy s. J Immunother Cancer. 2022 Oct;10(10):e004867. doi: 10.1136/jitc-2022-004867. J Immunother Cancer. 2022. PMID: 36307149 Free PMC article.
Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival.
Delyon J, Mateus C, Lefeuvre D, Lanoy E, Zitvogel L, Chaput N, Roy S, Eggermont AM, Routier E, Robert C. Delyon J, et al. Among authors: roy s. Ann Oncol. 2013 Jun;24(6):1697-703. doi: 10.1093/annonc/mdt027. Epub 2013 Feb 24. Ann Oncol. 2013. PMID: 23439861 Free article.
A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted Agents.
Azan A, Caspers PJ, Bakker Schut TC, Roy S, Boutros C, Mateus C, Routier E, Besse B, Planchard D, Seck A, Kamsu Kom N, Tomasic G, Koljenović S, Noordhoek Hegt V, Texier M, Lanoy E, Eggermont AM, Paci A, Robert C, Puppels GJ, Mir LM. Azan A, et al. Among authors: roy s. Cancer Res. 2017 Jan 15;77(2):557-565. doi: 10.1158/0008-5472.CAN-16-1733. Epub 2016 Nov 11. Cancer Res. 2017. PMID: 27836854 Clinical Trial.
Arterial thrombosis and anti-PD-1 blockade.
Boutros C, Scoazec JY, Mateus C, Routier E, Roy S, Robert C. Boutros C, et al. Among authors: roy s. Eur J Cancer. 2018 Mar;91:164-166. doi: 10.1016/j.ejca.2017.11.018. Epub 2017 Dec 27. Eur J Cancer. 2018. PMID: 29289455 No abstract available.
Transcriptional response to hypoxic stress in melanoma and prognostic potential of GBE1 and BNIP3.
Buart S, Terry S, Noman MZ, Lanoy E, Boutros C, Fogel P, Dessen P, Meurice G, Gaston-Mathé Y, Vielh P, Roy S, Routier E, Marty V, Ferlicot S, Legrès L, Bouchtaoui ME, Kamsu-Kom N, Muret J, Deutsch E, Eggermont A, Soria JC, Robert C, Chouaib S. Buart S, et al. Among authors: roy s. Oncotarget. 2017 Oct 30;8(65):108786-108801. doi: 10.18632/oncotarget.22150. eCollection 2017 Dec 12. Oncotarget. 2017. PMID: 29312568 Free PMC article.
Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma.
Cerezo M, Guemiri R, Druillennec S, Girault I, Malka-Mahieu H, Shen S, Allard D, Martineau S, Welsch C, Agoussi S, Estrada C, Adam J, Libenciuc C, Routier E, Roy S, Désaubry L, Eggermont AM, Sonenberg N, Scoazec JY, Eychène A, Vagner S, Robert C. Cerezo M, et al. Among authors: roy s. Nat Med. 2018 Dec;24(12):1877-1886. doi: 10.1038/s41591-018-0217-1. Epub 2018 Oct 29. Nat Med. 2018. PMID: 30374200
Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma.
Moya-Plana A, Herrera Gómez RG, Rossoni C, Dercle L, Ammari S, Girault I, Roy S, Scoazec JY, Vagner S, Janot F, Eggermont AMM, Robert C. Moya-Plana A, et al. Among authors: roy s. Cancer Immunol Immunother. 2019 Jul;68(7):1171-1178. doi: 10.1007/s00262-019-02351-7. Epub 2019 Jun 7. Cancer Immunol Immunother. 2019. PMID: 31172258 Free PMC article.
Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma.
Boutros C, Chaput-Gras N, Lanoy E, Larive A, Mateus C, Routier E, Sun R, Tao YG, Massard C, Bahleda R, Schwob D, Ibrahim N, Khoury Abboud RM, Caramella C, Lancia A, Cassard L, Roy S, Soria JC, Robert C, Deutsch E. Boutros C, et al. Among authors: roy s. J Immunother Cancer. 2020 Aug;8(2):e000627. doi: 10.1136/jitc-2020-000627. J Immunother Cancer. 2020. PMID: 32819972 Free PMC article. Clinical Trial.
10,091 results
You have reached the last available page of results. Please see the User Guide for more information.